Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCP NASDAQ:CVKD NASDAQ:LGVN NASDAQ:QUCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.43+3.6%$1.22$0.86▼$2.67$19.72M1.51.77 million shs22,289 shsCVKDCadrenal Therapeutics$6.16-2.5%$6.24$4.21▼$16.50$18.90M1.8153,029 shs29,901 shsLGVNLongeveron$0.87+1.2%$0.90$0.48▼$1.80$20.22M-0.314.09 million shs100,674 shsQUCYMainz Biomed$0.37+0.8%$0.00$0.35▼$2.64$4.60M0.42775,872 shs43,581 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%-0.72%-8.61%+43.75%-8.91%CVKDCadrenal Therapeutics-0.47%+18.57%+34.47%+3.44%-61.32%LGVNLongeveron+0.60%-3.17%-19.99%+58.60%-42.93%QUCYMainz Biomed-11.35%-27.46%-20.54%+36,399,900.00%+36,399,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.43+3.6%$1.22$0.86▼$2.67$19.72M1.51.77 million shs22,289 shsCVKDCadrenal Therapeutics$6.16-2.5%$6.24$4.21▼$16.50$18.90M1.8153,029 shs29,901 shsLGVNLongeveron$0.87+1.2%$0.90$0.48▼$1.80$20.22M-0.314.09 million shs100,674 shsQUCYMainz Biomed$0.37+0.8%$0.00$0.35▼$2.64$4.60M0.42775,872 shs43,581 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%-0.72%-8.61%+43.75%-8.91%CVKDCadrenal Therapeutics-0.47%+18.57%+34.47%+3.44%-61.32%LGVNLongeveron+0.60%-3.17%-19.99%+58.60%-42.93%QUCYMainz Biomed-11.35%-27.46%-20.54%+36,399,900.00%+36,399,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 2.00Hold$6.00319.58% UpsideCVKDCadrenal Therapeutics 2.00Hold$13.00111.07% UpsideLGVNLongeveron 2.33Hold$5.50535.10% UpsideQUCYMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest QUCY, LGVN, CVKD, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/27/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/12/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)3/6/2026QUCYMainz Biomed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$0.46 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ALGVNLongeveron$1.20M16.81N/AN/A$0.25 per share3.46QUCYMainz Biomed$540K8.51N/AN/A$0.07 per share5.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$8.83M-$0.79N/AN/AN/AN/A-132.61%-89.83%5/21/2026 (Estimated)CVKDCadrenal Therapeutics-$13.24M-$6.68N/AN/AN/AN/A-333.30%-236.95%5/7/2026 (Estimated)LGVNLongeveron-$22.70M-$1.28N/AN/AN/A-1,893.58%-199.79%-143.21%5/7/2026 (Estimated)QUCYMainz Biomed-$16.21M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest QUCY, LGVN, CVKD, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026N/ACOCPCocrystal Pharma-$0.15N/AN/AN/AN/AN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51N/AN/AN/AN/AN/A5/7/2026Q1 2026LGVNLongeveron-$0.18N/AN/AN/A$0.35 millionN/A3/31/2026Q4 2025COCPCocrystal Pharma-$0.18-$0.17+$0.01-$0.17N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/31/2026Q4 2025QUCYMainz BiomedN/A-$0.0250N/A-$0.0250N/A$0.13 million3/17/2026Q4 2025LGVNLongeveron-$0.42-$0.22+$0.20-$0.22$0.11 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AQUCYMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A3.683.68CVKDCadrenal TherapeuticsN/A2.722.72LGVNLongeveron0.031.331.33QUCYMainz Biomed1.550.500.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%CVKDCadrenal Therapeutics7.92%LGVNLongeveron10.01%QUCYMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%CVKDCadrenal Therapeutics26.09%LGVNLongeveron11.20%QUCYMainz Biomed9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1013.79 million9.91 millionNot OptionableCVKDCadrenal Therapeutics43.08 million2.28 millionNot OptionableLGVNLongeveron2023.27 million20.66 millionNot OptionableQUCYMainz Biomed3012.52 million11.29 millionN/AQUCY, LGVN, CVKD, and COCP HeadlinesRecent News About These CompaniesQuantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense SectorsMarch 17, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQUCY, LGVN, CVKD, and COCP Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.43 +0.05 (+3.62%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Cadrenal Therapeutics NASDAQ:CVKD$6.16 -0.16 (-2.55%) As of 10:51 AM Eastern This is a fair market value price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Longeveron NASDAQ:LGVN$0.87 +0.01 (+1.16%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Mainz Biomed NASDAQ:QUCY$0.37 +0.00 (+0.82%) As of 10:50 AM Eastern This is a fair market value price provided by Massive. Learn more.Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
